Biotech, Deals, Partnering

Covidien enters in to a biotech deal with Integra Lifesciences

Posted on 29 October 2013

Tags: , , ,

Covidien has entered into a biotech deal with a definitive agreement with Integra LifeSciences Corporation to sell its Confluent Surgical product line.

The transaction is expected to close by March 31, 2014, subject to receipt of regulatory approvals.

Covidien will receive an initial cash payment of $235 million from Integra upon the closing of the transaction for this biotech deal.

Covidien may receive up to $30 million, contingent upon the achievement of certain performance measures related to the transition of the Confluent Surgical business to Integra.

Confluent Surgical products include: DuraSeal, DuraSeal Exact/Xact, VascuSeal and SprayShield

These products are part of the soft tissue repair category of Covidien’s Medical Devices business and generated approximately $65 million in sales in fiscal 2012.

For further deal information visit Current Agreements (subscription required)



Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter


Print Friendly, PDF & Email

Leave a Reply